2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network

Julie A. Bettinger; Gaston De Serres; Louis Valiquette; Otto G. Vanderkooi; James D. Kellner; Brenda L. Coleman; Karina A. Top; Jennifer E. Isenor; Anne E. McCarthy

doi:10.2807/1560-7917.ES.2020.25.22.1900470

2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network

Julie A. Bettinger, Gaston De Serres, Louis Valiquette, Otto G. Vanderkooi, James D. Kellner, Brenda L. Coleman, Karina A. Top, Jennifer E. Isenor, Anne E. McCarthy

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

11 Citas (Scopus)

Resumen

Background: The Canadian National Vaccine Safety (CANVAS) network monitors the safety of seasonal influenza vaccines in Canada. Aim: To provide enhanced surveillance for seasonal influenza and pandemic influenza vaccines. Methods: In 2017/18 and 2018/19 influenza seasons, adults (. 15 years of age) and parents of children vaccinated with the seasonal influenza vaccine participated in an observational study using web-based active surveillance. Participants completed an online survey for health events occurring in the first 7 days after vaccination. Participants who received the influenza vaccine in the previous season, but had not yet been vaccinated for the current season, were unvaccinated controls. Results: In 2017/18, 43,751 participants and in 2018/19, 47,798 completed the online safety survey. In total, 957 of 30,173 participants vaccinated in 2017/18 (3.2%; 95% confidence interval (CI): 3.0.3.4) and 857 of 25,799 participants vaccinated in 2018/19 (3.3%; 95% CI: 3.1.3.5) reported a health problem of sufficient intensity to prevent their normal daily activities and/or cause them to seek medical care (including hospitalisation). This compared to 323 of 13,578 (2.4%; 95% CI: 2.1.2.6) and 544 of 21,999 (2.5%; 95% CI: 2.3.2.7) controls in each respective season. The event rate in vaccinated adults and children was higher than the background rate and was associated with specific influenza vaccines. The higher rate of events was associated with systemic symptoms and migraines/headaches. Conclusion: In 2017/18 and 2018/19, higher rates of events were reported following seasonal influenza vaccination than in the pre-vaccination period. This signal was associated with several seasonal influenza vaccine products.

Idioma original	English
Publicación	Eurosurveillance
Volumen	25
N.º	22
DOI	https://doi.org/10.2807/1560-7917.ES.2020.25.22.1900470
Estado	Published - 2020

Nota bibliográfica

Funding Information:
JAB, OGV, BLC and AEM none. GDS has received grants for investigator-initiated studies unrelated to influenza vaccine from Pfizer and provided paid expert testimony for the Ontario Nurses Association, the Quebec Ministry of Justice and GSK. LV has served on advisory boards for Merck, Abbott, and Wyeth and has received compensation to conduct clinical trials involving antibacterials and C. difficile vaccines from Sanofi, GSK, Wyeth, Pfizer, Cubist, Merck, and Actelion. KAT has received grants from GSK and consultancy fees from Pfizer outside the submitted work. JDK has received investigator initiated funding for epidemiologic research from Pfizer and contract clinical trial funding from Merck. JEI has received grants from GSK and Sanofi outside the submitted work.

Funding Information:
Funding Statement: The Canadian National Vaccine Safety Network as part of the Canadian Immunization Research Network is funded by a research grant from the Canadian Institutes of Health Research and the Public Health Agency of Canada grant #151944 (1 June 2017–31 December 2022). See www.cirnetwork.ca/ annual reports for details on the network.

Publisher Copyright:
© 2020 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

ASJC Scopus Subject Areas

Epidemiology
Public Health, Environmental and Occupational Health
Virology

PubMed: MeSH publication types

Journal Article
Observational Study
Research Support, Non-U.S. Gov't

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.2807/1560-7917.ES.2020.25.22.1900470

Otros archivos y enlaces

Citar esto

@article{5153bf66668246b8aa2dbc60be3a15be,

title = "2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network",

abstract = "Background: The Canadian National Vaccine Safety (CANVAS) network monitors the safety of seasonal influenza vaccines in Canada. Aim: To provide enhanced surveillance for seasonal influenza and pandemic influenza vaccines. Methods: In 2017/18 and 2018/19 influenza seasons, adults (. 15 years of age) and parents of children vaccinated with the seasonal influenza vaccine participated in an observational study using web-based active surveillance. Participants completed an online survey for health events occurring in the first 7 days after vaccination. Participants who received the influenza vaccine in the previous season, but had not yet been vaccinated for the current season, were unvaccinated controls. Results: In 2017/18, 43,751 participants and in 2018/19, 47,798 completed the online safety survey. In total, 957 of 30,173 participants vaccinated in 2017/18 (3.2%; 95% confidence interval (CI): 3.0.3.4) and 857 of 25,799 participants vaccinated in 2018/19 (3.3%; 95% CI: 3.1.3.5) reported a health problem of sufficient intensity to prevent their normal daily activities and/or cause them to seek medical care (including hospitalisation). This compared to 323 of 13,578 (2.4%; 95% CI: 2.1.2.6) and 544 of 21,999 (2.5%; 95% CI: 2.3.2.7) controls in each respective season. The event rate in vaccinated adults and children was higher than the background rate and was associated with specific influenza vaccines. The higher rate of events was associated with systemic symptoms and migraines/headaches. Conclusion: In 2017/18 and 2018/19, higher rates of events were reported following seasonal influenza vaccination than in the pre-vaccination period. This signal was associated with several seasonal influenza vaccine products.",

author = "Bettinger, {Julie A.} and Serres, {Gaston De} and Louis Valiquette and Vanderkooi, {Otto G.} and Kellner, {James D.} and Coleman, {Brenda L.} and Top, {Karina A.} and Isenor, {Jennifer E.} and McCarthy, {Anne E.}",

note = "Funding Information: JAB, OGV, BLC and AEM none. GDS has received grants for investigator-initiated studies unrelated to influenza vaccine from Pfizer and provided paid expert testimony for the Ontario Nurses Association, the Quebec Ministry of Justice and GSK. LV has served on advisory boards for Merck, Abbott, and Wyeth and has received compensation to conduct clinical trials involving antibacterials and C. difficile vaccines from Sanofi, GSK, Wyeth, Pfizer, Cubist, Merck, and Actelion. KAT has received grants from GSK and consultancy fees from Pfizer outside the submitted work. JDK has received investigator initiated funding for epidemiologic research from Pfizer and contract clinical trial funding from Merck. JEI has received grants from GSK and Sanofi outside the submitted work. Funding Information: Funding Statement: The Canadian National Vaccine Safety Network as part of the Canadian Immunization Research Network is funded by a research grant from the Canadian Institutes of Health Research and the Public Health Agency of Canada grant #151944 (1 June 2017–31 December 2022). See www.cirnetwork.ca/ annual reports for details on the network. Publisher Copyright: {\textcopyright} 2020 European Centre for Disease Prevention and Control (ECDC). All rights reserved.",

year = "2020",

doi = "10.2807/1560-7917.ES.2020.25.22.1900470",

language = "English",

volume = "25",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "Centre Europeen pour la Surveillance Epidemiologique du SIDA",

number = "22",

}

TY - JOUR

T1 - 2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network

AU - Bettinger, Julie A.

AU - Serres, Gaston De

AU - Valiquette, Louis

AU - Vanderkooi, Otto G.

AU - Kellner, James D.

AU - Coleman, Brenda L.

AU - Top, Karina A.

AU - Isenor, Jennifer E.

AU - McCarthy, Anne E.

N1 - Funding Information: JAB, OGV, BLC and AEM none. GDS has received grants for investigator-initiated studies unrelated to influenza vaccine from Pfizer and provided paid expert testimony for the Ontario Nurses Association, the Quebec Ministry of Justice and GSK. LV has served on advisory boards for Merck, Abbott, and Wyeth and has received compensation to conduct clinical trials involving antibacterials and C. difficile vaccines from Sanofi, GSK, Wyeth, Pfizer, Cubist, Merck, and Actelion. KAT has received grants from GSK and consultancy fees from Pfizer outside the submitted work. JDK has received investigator initiated funding for epidemiologic research from Pfizer and contract clinical trial funding from Merck. JEI has received grants from GSK and Sanofi outside the submitted work. Funding Information: Funding Statement: The Canadian National Vaccine Safety Network as part of the Canadian Immunization Research Network is funded by a research grant from the Canadian Institutes of Health Research and the Public Health Agency of Canada grant #151944 (1 June 2017–31 December 2022). See www.cirnetwork.ca/ annual reports for details on the network. Publisher Copyright: © 2020 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

PY - 2020

Y1 - 2020

N2 - Background: The Canadian National Vaccine Safety (CANVAS) network monitors the safety of seasonal influenza vaccines in Canada. Aim: To provide enhanced surveillance for seasonal influenza and pandemic influenza vaccines. Methods: In 2017/18 and 2018/19 influenza seasons, adults (. 15 years of age) and parents of children vaccinated with the seasonal influenza vaccine participated in an observational study using web-based active surveillance. Participants completed an online survey for health events occurring in the first 7 days after vaccination. Participants who received the influenza vaccine in the previous season, but had not yet been vaccinated for the current season, were unvaccinated controls. Results: In 2017/18, 43,751 participants and in 2018/19, 47,798 completed the online safety survey. In total, 957 of 30,173 participants vaccinated in 2017/18 (3.2%; 95% confidence interval (CI): 3.0.3.4) and 857 of 25,799 participants vaccinated in 2018/19 (3.3%; 95% CI: 3.1.3.5) reported a health problem of sufficient intensity to prevent their normal daily activities and/or cause them to seek medical care (including hospitalisation). This compared to 323 of 13,578 (2.4%; 95% CI: 2.1.2.6) and 544 of 21,999 (2.5%; 95% CI: 2.3.2.7) controls in each respective season. The event rate in vaccinated adults and children was higher than the background rate and was associated with specific influenza vaccines. The higher rate of events was associated with systemic symptoms and migraines/headaches. Conclusion: In 2017/18 and 2018/19, higher rates of events were reported following seasonal influenza vaccination than in the pre-vaccination period. This signal was associated with several seasonal influenza vaccine products.

AB - Background: The Canadian National Vaccine Safety (CANVAS) network monitors the safety of seasonal influenza vaccines in Canada. Aim: To provide enhanced surveillance for seasonal influenza and pandemic influenza vaccines. Methods: In 2017/18 and 2018/19 influenza seasons, adults (. 15 years of age) and parents of children vaccinated with the seasonal influenza vaccine participated in an observational study using web-based active surveillance. Participants completed an online survey for health events occurring in the first 7 days after vaccination. Participants who received the influenza vaccine in the previous season, but had not yet been vaccinated for the current season, were unvaccinated controls. Results: In 2017/18, 43,751 participants and in 2018/19, 47,798 completed the online safety survey. In total, 957 of 30,173 participants vaccinated in 2017/18 (3.2%; 95% confidence interval (CI): 3.0.3.4) and 857 of 25,799 participants vaccinated in 2018/19 (3.3%; 95% CI: 3.1.3.5) reported a health problem of sufficient intensity to prevent their normal daily activities and/or cause them to seek medical care (including hospitalisation). This compared to 323 of 13,578 (2.4%; 95% CI: 2.1.2.6) and 544 of 21,999 (2.5%; 95% CI: 2.3.2.7) controls in each respective season. The event rate in vaccinated adults and children was higher than the background rate and was associated with specific influenza vaccines. The higher rate of events was associated with systemic symptoms and migraines/headaches. Conclusion: In 2017/18 and 2018/19, higher rates of events were reported following seasonal influenza vaccination than in the pre-vaccination period. This signal was associated with several seasonal influenza vaccine products.

UR - http://www.scopus.com/inward/record.url?scp=85086016928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85086016928&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2020.25.22.1900470

DO - 10.2807/1560-7917.ES.2020.25.22.1900470

M3 - Article

C2 - 32524947

AN - SCOPUS:85086016928

SN - 1025-496X

VL - 25

JO - Eurosurveillance

JF - Eurosurveillance

IS - 22

ER -

2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto